Surrozen (SRZN) AI Stock Analysis

• Market Cap: $307.21M
• Dividend Yield: N/A
• Average Volume (3M): 25.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.37
• Revenue Growth: -35.61%
• EPS Growth: -68.92%
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -41.33
• Shares Outstanding: 11,610,371
• 10 Day Avg. Volume: 29,706
• 30 Day Avg. Volume: 25,240
• PEG Ratio: -0.01
• Price to Book (P/B): -0.90
• Price to Sales (P/S): 48.61
• P/FCF Ratio: -5.56
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: 12.74
• Enterprise Value/Gross Profit: 12.85
• Enterprise Value/Ebitda: -0.92
• 1Y Price Target: $42.50
• Price Target Upside: 34.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -3.98
• Revenue Forecast (FY): $5.40M

• Rating: 45 Neutral
• Price Target: $29.00 ▼(-8.11% Downside)
• Action: Reiterated
• Date: 05/15/26

Positive Factors

Regenerative platform focus

Surrozen’s platform targets Wnt signaling to stimulate tissue repair across liver, intestine, eye and other organs. A platform approach addressing multiple high-unmet-need indications supports durable R&D leverage, licensing opportunities and long-term strategic partnerships.

Negative Factors

Negative shareholders' equity

Negative shareholders’ equity indicates accumulated losses have eroded the capital base, reducing financial flexibility. This structural weakness constrains borrowing capacity, increases dependence on dilutive financings and elevates long-term funding risk for clinical development.

Surrozen Business Overview & Revenue Model

Company Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, ...

Read more

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, ...

How the Company Makes Money

Surrozen does not primarily generate revenue from product sales because it is a clinical-stage biotechnology company and, to the extent publicly available information indicates, it has no approved commercial products. Instead, when it earns revenu...

Read more

Surrozen does not primarily generate revenue from product sales because it is a clinical-stage biotechnology company and, to the extent publicly available information indicates, it has no approved commercial products. Instead, when it earns revenu...

Surrozen Financial Statement Overview

Breakdown	TTM	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.49M	3.48M	10.65M	0.00	12.50M	0.00
Gross Profit	7.43M	2.94M	10.65M	-27.23M	9.23M	-3.30M
EBITDA	-103.51M	-41.55M	-24.10M	-41.13M	-42.38M	-51.35M
Net Income	-342.56M	-242.03M	-63.56M	-43.04M	-36.00M	-52.51M
Balance Sheet
Total Assets	120.71M	98.73M	48.47M	46.08M	89.44M	137.17M
Cash, Cash Equivalents and Short-Term Investments	106.91M	89.25M	34.56M	36.04M	75.84M	101.85M
Total Debt	6.78M	6.64M	8.47M	3.38M	5.60M	7.79M
Total Liabilities	398.86M	286.49M	69.85M	8.14M	13.43M	27.47M
Stockholders Equity	-278.15M	-187.76M	-21.38M	37.94M	76.00M	109.70M
Cash Flow
Free Cash Flow	-33.68M	-30.37M	-17.65M	-40.76M	-44.87M	-50.08M
Operating Cash Flow	-33.46M	-30.24M	-17.63M	-40.36M	-44.15M	-48.81M
Investing Cash Flow	-221.00K	-128.00K	-26.00K	51.72M	38.31M	-77.71M
Financing Cash Flow	38.95M	85.05M	16.18M	276.00K	-2.56M	124.63M

Surrozen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Negative. The current price of 31.56 is above the 20-day moving average (MA) of 29.30, above the 50-day MA of 28.95, and above the 200-day MA of 20.43, indicating a neutral trend. The MACD of -1.03 indicates Positive momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRZN.

Surrozen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	54 Neutral	$474.07M	-8.05	-22.51%	―	1199.64%	30.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STTK	50 Neutral	$464.68M	-13.43	-60.73%	―	-78.29%	54.16%
IRD	48 Neutral	$336.98M	-34.13	6068.79%	―	-12.22%	30.28%
BMEA	48 Neutral	$98.33M	-2.22	-196.72%	―	―	74.83%
SPRB	47 Neutral	$136.29M	-1.81	-155.40%	―	-100.00%	61.98%
SRZN	45 Neutral	$307.21M	-0.84	309.79%	―	-35.61%	-68.92%

Surrozen Corporate Events